Charles Douglas Blundell

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK.

Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom.

Part of Istesso Ltd., Modern Biosciences Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in London, UK. The company was founded by Samuel Cameron Williams, Alexander James Stevenson. Samuel Cameron Williams has been the CEO since incorporation.

Pharminox Ltd develops treatments for cancer therapy. The private company is based in Abingdon, UK. The British company was founded by Neil L. Brown.

Centauri Ltd. provides information technology consulting services. The private company is based in Hertfordshire, UK.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

Aquarius Equity Holdings Ltd. functions as an investment holding British company. The private company is based in Manchester, UK. and has subsidiaries in United Kingdom.

Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Ieso Digital Health Ltd. provides Internet enabled mental health services to health providers, private individuals and businesses. The firm engages in delivering cognitive behavioral therapy. It offers anxiety, bereavement, child and family, depression, drug and alcohol misuse, eating disorder, managing anger, managing pain, obsessive compulsive disorder, panic, phobia, post traumatic stress, relationship, sexual difficulty, sports psychology, stress management, and terminal illness therapy services. The company was founded by Barnaby Perks, Sue Wright and Nadine Field in 2000 and is headquartered in Cambridge, the United Kingdom.

Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

Part of 4D Pharma Plc, The Microbiota Co. Ltd. develops a patented bacteria which treats irritable bowel syndrome and related symptoms. The company is based in Manchester, UK. The Microbiota Co. was acquired by 4D Pharma Plc on July 18, 2014 for $1.65 million.

Modern Biosciences Nominees Ltd. acts as a nominee, trust, and depository.

Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom.

Istesso Ltd. Operates as a drug discovery and development company. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy.

Touchlight Holdings Ltd. is an investment holding British company founded in 2014. The private company is based in London, UK. The company's main function is to hold investments.

Touchlight IP Ltd. was founded in 2014 and engages in leasing intellectual property and related products. The private company is based in London, UK.

Imperagen Ltd. is a British biotechnology company founded in 2021 that engages in research and experimental development. The company is based in Manchester, UK.